A number of research firms have changed their ratings and price targets for Y-mAbs Therapeutics (NASDAQ: YMAB): 11/12/2020 – Y-mAbs Therapeutics had its price target raised by analysts at Morgan Stanley from $42.00 to $45.00. They now have an “equal weight” rating on the stock. 11/9/2020 – Y-mAbs Therapeutics had its price target raised by […]